Protocol Ledger

NCT05671510 · Phase III · ACTIVE NOT RECRUITING

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Interventional Phase III clinical trial protocol NCT05671510 sponsored by OncoC4 in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-28 Enrollment: 630 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05671510
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)630 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05671510
Protocol FieldVerified Registry Value
NCT IdentifierNCT05671510
Consolidated Lead SponsorOncoC4
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment630 participants (ESTIMATED)
Registered Start Date2023-06-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI